Cellartis and ReproCELL Sign Agreement to Provide CardioToxicity screening service using hESC derived Cardiomyocytes


Cellartis AB, a premier provider of stem cell derived products and technologies, and ReproCELL, a Japanese biotechnology company on the forefront of stem cell platforms and screening solutions, have today signed an agreement whereby ReproCELL can commercialise its QTempo Cardiotoxicity platform using beating human embryonic stem cell (hESC) derived Cardiomyocytes from Cellartis on a fee for service basis.

In this first of a kind deal, cardiotoxicity testing via the ReproCELL QTempo platform will be commercially available using live and beating hESC derived cardiomyocytes to provide more accurate models of in vivo physiology. It is expected that the QTempo platform will emerge as the next generation solution to commercial hERG screening, which represents the current FDA gold standard for cardiac safety testing.

“This is a great moment for us, in terms of bundling our cell expertise with a screening platform for commercial means, and we are very pleased to partner with ReproCELL” said Mats Lundwall, CEO. “Ultimately, this deal reflects a trend we hope to continue as we build on our momentum and continue to reinforce the positivity felt for Cellartis and the stem cell space itself “.

ReproCELL’s CEO, Chikafumi Yokoyama, noted “Cardiotoxicity is a common cause of withdrawal drugs from the market. More accurate pre-clinical tests are vital for improving both patient safety and drug development efficiency. The combination of Cellartis’s hESC cardiomyocyte technology with ReproCELL’s QTempo platform is an exciting development”.